- Home
- TNGX vs RUN Comparison
TNGX vs RUN Comparison
Compare TNGX & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | RUN |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TNGX | RUN |
|---|---|---|
| Price | $23.35 | $13.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $21.78 | $18.80 |
| AVG Volume (30 Days) | 2.8M | ★ 7.9M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.89 | ★ 113.35 |
| EPS | N/A | ★ 0.62 |
| Revenue | $62,384,000.00 | ★ $858,578,000.00 |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | N/A | $4.54 |
| P/E Ratio | ★ N/A | $7.56 |
| Revenue Growth | ★ 48.29 | 12.97 |
| 52 Week Low | $1.12 | $5.38 |
| 52 Week High | $28.41 | $22.44 |
Technical Indicators
Market Signals| Indicator | TNGX | RUN |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 55.60 |
| Support Level | $7.08 | $11.84 |
| Resistance Level | $28.41 | $14.72 |
| Average True Range (ATR) | 1.80 | 0.77 |
| MACD | -0.47 | 0.17 |
| Stochastic Oscillator | 34.51 | 50.72 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About RUN Sunrun Inc.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.